Sökresultat - Katja Weisel

Sarcopenia and fat loss from serial CT predict survival in multiple myeloma patients undergoing stem cell transplantation av Julian Kylies, Elias Brauneck, Matthias Priemel, Dominik Kylies, Katja Weisel, Leon-Gordian Leonhardt, Lennart Viezens

Hämta fulltext

Predicting survival of patients with spinal involvement in multiple myeloma using PATHFx 3.0 – a validation study of 100 patients in Germany av Julian Kylies, Elias Brauneck, Tobias M. Ballhause, Katja Weisel, Markus Schomacher, Malte Schroeder, Peter Obid, Leon-Gordian Leonhardt, Lennart Viezens

Hämta fulltext

CD38-specific nanobody-based bispecific antibody recruiters (BARs) redirect complement-dependent cytotoxicity toward multiple myeloma cells av Luca Julius Pape, Anna Josephine Gebhardt, Marten Dannenberg, Henry Risch, Anya Duttmann, Katja Weisel, Julia Hambach, Friedrich Koch-Nolte, Peter Bannas

Hämta fulltext

P908: IDENTIFICATION OF CYTOKINES ASSOCIATED WITH RESPONSE AND CYTOKINE RELEASE SYNDROME – ANALYSIS OF MAGNETISMM-3 COHORT A av Katja Weisel, Nizar J Bahlis, Paula Rodríguez-Otero, Andrea Viqueira, Shen-Wu Wang, Sangeetha Sathiah, Douglas Robinson, Thomas O’brien, Hang Quach

Hämta fulltext

Outcome of critically ill patients receiving systemic chemotherapy on the intensive care unit av Panagiotis Karagiannis, Felix Klingler, Viktor Arelin, Winfried Alsdorf, Christina König, Kevin Roedl, Walter Fiedler, Katja Weisel, Stefan Kluge, Carsten Bokemeyer, Dominic Wichmann

Hämta fulltext

P906: GENOMIC ANALYSIS TO IDENTIFY DETERMINANTS OF INHERENT RESPONSE AND RESISTANCE TO ELRANATAMAB IN MAGNETISMM-3 COHORT A av Paula Rodríguez-Otero, Hang Quach, Katja Weisel, Andrea Viqueira, Shen-Wu Wang, Phineas T. Hamilton, Tao Xie, Thomas O’brien, Nizar J Bahlis

Hämta fulltext

PB2090: SYSTEMATIC LITERATURE REVIEW OF PROGNOSTIC FACTORS FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA av Shaji Kumar, Xavier Leleu, Katja Weisel, Rakesh Popat, Samantha Craigie, Leena Patel, Abril Oliva Ramirez, Wenzhen Ge, Qiufei MA, Christian Hampp, Sundar Jagannath

Hämta fulltext

Correction: The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development av Pralay Mukhopadhyay, Hesham A. Abdullah, Joanna B. Opalinska, Prani Paka, Eric Richards, Katja Weisel, Suzanne Trudel, Maria-Victoria Mateos, Meletios Athanasios Dimopoulos, Sagar Lonial

Hämta fulltext

The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development av Pralay Mukhopadhyay, Hesham A. Abdullah, Joanna B. Opalinska, Prani Paka, Eric Richards, Katja Weisel, Suzanne Trudel, Maria-Victoria Mateos, Meletios Athanasios Dimopoulos, Sagar Lonial

Hämta fulltext

Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-related Quality of Life for Patients With Relapsed/Refractory Multiple Myeloma: Final Data From the Phase 2 ELOQUENT-... av Katja Weisel, Meletios A. Dimopoulos, Jesús San-Miguel, Agne Paner, Monika Engelhardt, Fiona Taylor, Jennifer Lord-Bessen, Christine Yip, Mike Greenwood, Jackson Tang, Michele Cavo

Hämta fulltext

PB2088: ABBV-383 IN COMBINATION WITH ANTI-CANCER REGIMENS IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: DOSE ESCALATION AND EXPANSION av Cesar Rodriguez Valdes, Katja Weisel, Rachid Baz, Akshanth Polepally, Jeremy A. Ross, Ziyi Jin, Kristin D’amico, Orlando F. Bueno, Leanne Lash Fleming, Peter Voorhees

Hämta fulltext

P964: PATIENT (PT)-REPORTED OUTCOMES IN PTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH BELANTAMAB MAFODOTIN (BELAMAF) VS POMALIDOMIDE/LOW DOSE DEXAMETHASONE (PD)... av Vania Hungria, Katja Weisel, Brooke Currie, Sue Perera, Neal Sule, Wei He, Astrid Mckeown, Sandhya Sapra, Linda Nelsen, Mary LI, Sophie Barale, Julia Boyle, Kaytlyn Mcpoyle, Meletios A. Dimopoulos

Hämta fulltext

Identification of New Antibodies Targeting Malignant Plasma Cells for Immunotherapy by Next-Generation Sequencing-Assisted Phage Display av Steffen Krohn, Ammelie Svea Boje, Carina Lynn Gehlert, Sebastian Lutz, Nikos Darzentas, Henrik Knecht, Dietrich Herrmann, Monika Brüggemann, Axel J. Scheidig, Katja Weisel, Martin Gramatzki, Matthias Peipp, Katja Klausz

Hämta fulltext

Hepatitis E virus infections in people with multiple myeloma: an emerging challenge in the era of immunotherapeutic approaches av Maximilian Al-Bazaz, Sven Pischke, Winfried Alsdorf, Piet Sonnemann, Sophia Cichutek, Julian Schulze zur Wiesch, Christoph Schaefers, Jule Artzenroth, Lisa Leypoldt, Abdulaziz Kamili, Carsten Bokemeyer, Katja Weisel, Ricardo Kosch

Hämta fulltext

Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma av Niels Weinhold, Desiree Kirn, Anja Seckinger, Thomas Hielscher, Martin Granzow, Uta Bertsch, Gerlinde Egerer, Hans Salwender, Igor W. Blau, Katja Weisel, Jens Hillengass, Marc S. Raab, Dirk Hose, Hartmut Goldschmidt, Anna Jauch

Hämta fulltext

Measurable Residual Disease Testing in Multiple Myeloma Routine Clinical Practice: A Modified Delphi Study av Karthik Ramasamy, Hervé Avet-Loiseau, Cecilie Hveding Blimark, Michel Delforge, Francesca Gay, Salomon Manier, Joaquín Martinez-Lopez, Maria Victoria Mateos, Mohamad Mohty, Niels W.C.J. van de Donk, Katja Weisel

Hämta fulltext

PB2133: TRIAL IN PROGRESS: LINKER-MM3, A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF LINVOSELTAMAB VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD) IN RELAPSED/REFRACTORY MULT... av Katja Weisel, Vania Hungria, Hang Quach, Sung-Soo Yoon, Paula Rodríguez-Otero, Glenn Kroog, Arijit Sinha, Anita Boyapati, Charlotte Lyon, Karen Rodriguez Lorenc, Timothy Inocencio, James Harnett, Lei Chi, Vygngley Moore, Peter Voorhees

Hämta fulltext

Characteristics, treatment regimens, and outcomes of patients with true extramedullary multiple myeloma: a real-world monocentric analysis av Marie Harzer, Nils Gross-Fengels, Fede Melzer, Isabel Molwitz, Ricardo Kosch, Maximilian Al-Bazaz, Jule Artzenroth, Leon Cords, Leandra Bartke, Abdulaziz Kamili, Winfried Alsdorf, Carsten Bokemeyer, Katja Weisel, Lisa B. Leypoldt, Christoph Schaefers

Hämta fulltext

Belantamab mafodotin does not induce B-cell maturation antigen loss or systemic immune dysfunction in multiple myeloma av Hanny Musa, Michał Mielnik, Suzanne Trudel, Katja Weisel, Taryn Mockus-Daehn, Geraldine Ferron-Brady, Qingqing Hong, Yinjiao Ma, Sagar Patel, Sunil Suchindran, Xiangdong Zhou, Paul G. Richardson, Adam D. Cohen, Daniel E. Lowther

Hämta fulltext

Multiple myeloma in the young: insights on prognosis, clinical features and treatment outcome derived from nationwide German registry data and a nested multicenter sample av Abdulaziz Kamili, Paymon Ahmadi, Lisa Leypoldt, Franziska Marquard, Christoph Schaefers, Ricardo Kosch, Frederik Peters, Henrik Kusche, Tanja Zamrik, Christine Hanoun, Maximilian Seib, Evgenii Shumilov, Theo Leitner, Cyrus Khandanpour, Carsten Bokemeyer, Katja Weisel, Susanne Ghandili

Hämta fulltext